Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prednisone + olverembatinib + blinatumomab + chidamide
- Development stage
- Preclinical
- Lead developer
- Ascentage Pharma
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of prednisone (a corticosteroid), olverembatinib (a third-generation BCR-ABL tyrosine kinase inhibitor), blinatumomab (a bispecific T-cell engager antibody), and chidamide (a histone deacetylase inhibitor). This regimen likely combines multiple mechanisms of action to target hematological malignancies, particularly leukemias that may be resistant to standard therapies.
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)FGFR2 (Keratinocyte growth factor receptor)FLT3 (Fms related receptor tyrosine kinase 3)GR (Glucocorticoid receptor)HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)MR (Mineralocorticoid receptor)PDGFRA (Platelet-derived growth factor receptor alpha)SFK (SRC family kinases)
Beyond the preview
Go deeper on prednisone + olverembatinib + blinatumomab + chidamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prednisone + olverembatinib + blinatumomab + chidamide.